Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Abstract: Hepatitis C is a serious global health problem that affects over 50 million people worldwide. One million new cases occur every year, and cirrhosis and liver cancer are associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results